Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

IGFBP-rP1, a potential molecule associated with colon cancer differentiation

Authors: Wenjing Ruan, Shuzhen Zhu, Haibing Wang, Fangying Xu, Hong Deng, Yu Ma, Maode Lai

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

In our previous studies, we have demonstrated that insulin-like growth factor binding protein-related protein1 (IGFBP-rP1) played its potential tumor suppressor role in colon cancer cells through apoptosis and senescence induction. In this study, we will further uncover the role of IGFBP-rP1 in colon cancer differentiation and a possible mechanism by revealing responsible genes.

Results

In normal colon epithelium, immunohistochemistry staining detected a gradient IGFBP-rP1 expression along the axis of the crypt. IGFBP-rP1 strongly expressed in the differentiated cells at the surface of the colon epithelium, while weakly expressed at the crypt base. In colon cancer tissues, the expression of IGFBP-rP1 correlated positively with the differentiation status. IGFBP-rP1 strongly expressed in low grade colorectal carcinoma and weakly expressed in high grade colorectal carcinoma. In vitro, transfection of PcDNA3.1(IGFBP-rP1) into RKO, SW620 and CW2 cells induced a more pronounced anterior-posterior polarity morphology, accompanied by upregulation with alkaline phosphatase (AKP) activity. Upregulation of carcino-embryonic antigen (CEA) was also observed in SW620 and CW2 transfectants. The addition of IGFBP-rP1 protein into the medium could mimic most but not all effects of IGFBP-rP1 cDNA transfection. Seventy-eight reproducibly differentially expressed genes were detected in PcDNA3.1(IGFBP-rP1)-RKO transfectants, using Affymetrix 133 plus 2.0 expression chip platform. Directed Acyclic Graph (DAG) of the enriched GO categories demonstrated that differential expression of the enzyme regulator activity genes together with cytoskeleton and actin binding genes were significant. IGFBP-rP1 could upreguate Transgelin (TAGLN), downregulate SRY (sex determining region Y)-box 9(campomelic dysplasia, autosomal sex-reversal) (SOX9), insulin receptor substrate 1(IRS1), cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2B), amphiregulin(schwannoma-derived growth factor) (AREG) and immediate early response 5-like(IER5L) in RKO, SW620 and CW2 colon cancer cells, verified by Real time Reverse Transcription Polymerase Chain Reaction (rtRT-PCR). During sodium butyrate-induced Caco2 cell differentiation, IGFBP-rP1 was upregulated and the expression showed significant correlation with the AKP activity. The downregulation of IRS1 and SOX9 were also induced by sodium butyrate.

Conclusion

IGFBP-rP1 was a potential key molecule associated with colon cancer differentiation. Downregulation of IRS1 and SOX9 may the possible key downstream genes involved in the process.
Appendix
Available only for authorised users
Literature
1.
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995, 16: 3-34.PubMed
2.
Hwa V, Oh Y, Rosenfeld RG: The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999, 20: 761-787. 10.1210/er.20.6.761PubMed
3.
Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y: Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem. 1997, 272: 30729-30734. 10.1074/jbc.272.49.30729CrossRefPubMed
4.
Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG: Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem. 1996, 271: 30322-30325. 10.1074/jbc.271.48.30322CrossRefPubMed
5.
Murphy M, Pykett MJ, Harnish P, Zang KD, George DL: Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 1993, 4: 715-722.PubMed
6.
Swisshelm K, Ryan K, Tsuchiya K, Sager R: Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA. 1995, 92: 4472-4476. 10.1073/pnas.92.10.4472PubMedCentralCrossRefPubMed
7.
Akaogi K, Okabe Y, Sato J, Nagashima Y, Yasumitsu H, Sugahara K, Miyazaki K: Specific accumulation of tumor-derived adhesion factor in tumor blood vessels and in capillary tube-like structures of cultured vascular endothelial cells. Proc Natl Acad Sci USA. 1996, 93: 8384-8389. 10.1073/pnas.93.16.8384PubMedCentralCrossRefPubMed
8.
Yamauchi T, Umeda F, Masakado M, Isaji M, Mizushima S, Nawata H: Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells. Biochem J. 1994, 303 (Pt 2): 591-598.PubMedCentralCrossRefPubMed
9.
How HK, Yeoh A, Quah TC, Oh Y, Rosenfeld RG, Lee KO: Insulin-like growth factor binding proteins (IGFBPs) and IGFBP-related protein 1-levels in cerebrospinal fluid of children with acute lymphoblastic leukemia. J Clin Endocrinol Metab. 1999, 84: 1283-1287. 10.1210/jc.84.4.1283PubMed
10.
Vizioli MG, Sensi M, Miranda C, Cleris L, Formelli F, Anania MC, Pierotti MA, Greco A: IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene. 29: 3835-3844.
11.
Komatsu S, Okazaki Y, Tateno M, Kawai J, Konno H, Kusakabe M, Yoshiki A, Muramatsu M, Held WA, Hayashizaki Y: Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). Biochem Biophys Res Commun. 2000, 267: 109-117. 10.1006/bbrc.1999.1937CrossRefPubMed
12.
Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG, Perry A: Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol. 2002, 161: 665-672.PubMedCentralCrossRefPubMed
13.
Chen Y, Pacyna-Gengelbach M, Ye F, Knosel T, Lund P, Deutschmann N, Schluns K, Kotb WF, Sers C, Yasumoto H: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol. 2007, 211: 431-438. 10.1002/path.2132CrossRefPubMed
14.
Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res. 1999, 59: 2370-2375.PubMed
15.
Degeorges A, Wang F, Frierson HF, Seth A, Chung LW, Sikes RA: Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1. Cancer Res. 1999, 59: 2787-2790.PubMed
16.
Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM: Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res. 2003, 23: 2043-2051.PubMed
17.
Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R: Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004, 10: 6789-6795. 10.1158/1078-0432.CCR-04-0306CrossRefPubMed
18.
Luo MJ, Lai MD: Identification of differentially expressed genes in normal mucosa, adenoma and adenocarcinoma of colon by SSH. World J Gastroenterol. 2001, 7: 726-731.PubMed
19.
Lin J, Lai M, Huang Q, Ma Y, Cui J, Ruan W: Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression. J Pathol. 2007, 212: 83-90. 10.1002/path.2144CrossRefPubMed
20.
Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q, Lv B, Hu H, Lin J, Cui J: IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther. 2007, 6: 354-359. 10.4161/cbt.6.3.3702CrossRefPubMed
21.
Ma Y, Lu B, Ruan W, Wang H, Lin J, Hu H, Deng H, Huang Q, Lai M: Tumor suppressor gene insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) induces senescence-like growth arrest in colorectal cancer cells. Exp Mol Pathol. 2008, 85: 141-145. 10.1016/j.yexmp.2008.04.005CrossRefPubMed
22.
23.
Kato MV, Sato H, Tsukada T, Ikawa Y, Aizawa S, Nagayoshi M: A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells. Oncogene. 1996, 12: 1361-1364.PubMed
24.
Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR: Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 2002, 21: 140-147. 10.1038/sj.onc.1205021CrossRefPubMed
25.
Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K: Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 2002, 13: 205-213.PubMed
26.
Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR: Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008, 132: 363-374. 10.1016/j.cell.2007.12.032PubMedCentralCrossRefPubMed
27.
Tomlinson IP, Bodmer WF: Failure of programmed cell death and differentiation as causes of tumors: some simple mathematical models. Proc Natl Acad Sci USA. 1995, 92: 11130-11134. 10.1073/pnas.92.24.11130PubMedCentralCrossRefPubMed
28.
Corn PG, El-Deiry WS: Derangement of growth and differentiation control in oncogenesis. Bioessays. 2002, 24: 83-90. 10.1002/bies.10036CrossRefPubMed
29.
Vendrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, Pons M, Birnbaum D, Nguyen C, Theillet C, Cohen PA: Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004, 32: 397-414. 10.1677/jme.0.0320397CrossRefPubMed
30.
Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H: CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2003, 37: 44-57. 10.1002/gcc.10188CrossRefPubMed
31.
Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol. 2002, 160: 2169-2180.PubMedCentralCrossRefPubMed
32.
Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl R, Oberley TD: Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. Oncogene. 2003, 22: 1024-1034. 10.1038/sj.onc.1206210CrossRefPubMed
33.
Tohmiya Y, Koide Y, Fujimaki S, Harigae H, Funato T, Kaku M, Ishii T, Munakata Y, Kameoka J, Sasaki T: Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia. Tohoku J Exp Med. 2004, 204: 125-133. 10.1620/tjem.204.125CrossRefPubMed
34.
Shafat I, Zcharia E, Nisman B, Nadir Y, Nakhoul F, Vlodavsky I, Ilan N: An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun. 2006, 341: 958-963. 10.1016/j.bbrc.2006.01.048PubMedCentralCrossRefPubMed
35.
Shao L, Huang Q, Luo M, Lai M: Detection of the differentially expressed gene IGF-binding protein-related protein-1 and analysis of its relationship to fasting glucose in Chinese colorectal cancer patients. Endocr Relat Cancer. 2004, 11: 141-148. 10.1677/erc.0.0110141CrossRefPubMed
36.
Boyd D, Florent G, Chakrabarty S, Brattain D, Brattain MG: Alterations of the biological characteristics of a colon carcinoma cell line by colon-derived substrata material. Cancer Res. 1988, 48: 2825-2831.PubMed
37.
Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, Hirohashi S: Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res. 2001, 61: 2751-2758.PubMed
38.
Abbasi AM, Chester KA, MacPherson AJ, Boxer GM, Begent RH, Malcolm AD: Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas. J Pathol. 1992, 168: 405-411. 10.1002/path.1711680411CrossRefPubMed
39.
Velcich A, Palumbo L, Jarry A, Laboisse C, Racevskis J, Augenlicht L: Patterns of expression of lineage-specific markers during the in vitro-induced differentiation of HT29 colon carcinoma cells. Cell Growth Differ. 1995, 6: 749-757.PubMed
40.
Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB: Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000, 60: 749-755.PubMed
41.
Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li G, An X, Zhang Y: Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology. 2007, 132: 1066-1076. 10.1053/j.gastro.2006.12.004CrossRefPubMed
42.
Yang L, Olsson B, Pfeifer D, Jonsson JI, Zhou ZG, Jiang X, Fredriksson BA, Zhang H, Sun XF: Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells. Oncogene. 29: 516-526.
43.
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998, 4: 1046-1052. 10.1038/2030CrossRefPubMed
44.
Augenlicht L, Velcich A, Heerdt BG: Short-chain fatty acids and molecular and cellular mechanisms of colonic cell differentiation and transformation. Adv Exp Med Biol. 1995, 375: 137-148.CrossRefPubMed
45.
Matsumoto H, Erickson RH, Gum JR, Yoshioka M, Gum E, Kim YS: Biosynthesis of alkaline phosphatase during differentiation of the human colon cancer cell line Caco-2. Gastroenterology. 1990, 98: 1199-1207.PubMed
46.
Silberg DG, Swain GP, Suh ER, Traber PG: Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000, 119: 961-971. 10.1053/gast.2000.18142CrossRefPubMed
47.
48.
Lorentz O, Duluc I, Arcangelis AD, Simon-Assmann P, Kedinger M, Freund JN: Key role of the Cdx2 homeobox gene in extracellular matrix-mediated intestinal cell differentiation. J Cell Biol. 1997, 139: 1553-1565. 10.1083/jcb.139.6.1553PubMedCentralCrossRefPubMed
49.
Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR, Fearon ER: Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001, 159: 2239-2248.PubMedCentralCrossRefPubMed
50.
Freund JN, Domon-Dell C, Kedinger M, Duluc I: The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol. 1998, 76: 957-969. 10.1139/bcb-76-6-957CrossRefPubMed
51.
Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S: Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res. 2009, 15: 4665-4673. 10.1158/1078-0432.CCR-09-0401PubMedCentralCrossRefPubMed
52.
Domon-Dell C, Wang Q, Kim S, Kedinger M, Evers BM, Freund JN: Stimulation of the intestinal Cdx2 homeobox gene by butyrate in colon cancer cells. Gut. 2002, 50: 525-529. 10.1136/gut.50.4.525PubMedCentralCrossRefPubMed
53.
Qualtrough D, Hinoi T, Fearon E, Paraskeva C: Expression of CDX2 in normal and neoplastic human colon tissue and during differentiation of an in vitro model system. Gut. 2002, 51: 184-190. 10.1136/gut.51.2.184PubMedCentralCrossRefPubMed
54.
Blagosklonny MV: Apoptosis, proliferation, differentiation: in search of the order. Semin Cancer Biol. 2003, 13: 97-105. 10.1016/S1044-579X(02)00127-XCrossRefPubMed
55.
Wier ML, Scott RE: Regulation of the terminal event in cellular differentiation: biological mechanisms of the loss of proliferative potential. J Cell Biol. 1986, 102: 1955-1964. 10.1083/jcb.102.5.1955CrossRefPubMed
56.
Abrams JM: Competition and compensation: coupled to death in development and cancer. Cell. 2002, 110: 403-406. 10.1016/S0092-8674(02)00904-2CrossRefPubMed
57.
Li ZR, Hromchak R, Mudipalli A, Bloch A: Tumor suppressor proteins as regulators of cell differentiation. Cancer Res. 1998, 58: 4282-4287.PubMed
58.
Gandarillas A: Epidermal differentiation, apoptosis, and senescence: common pathways?. Exp Gerontol. 2000, 35: 53-62. 10.1016/S0531-5565(99)00088-1CrossRefPubMed
59.
Mitra RS, Wrone-Smith T, Simonian P, Foreman KE, Nunez G, Nickoloff BJ: Apoptosis in keratinocytes is not dependent on induction of differentiation. Lab Invest. 1997, 76: 99-107.PubMed
60.
Bauer NG, Richter-Landsberg C, Ffrench-Constant C: Role of the oligodendroglial cytoskeleton in differentiation and myelination. Glia. 2009, 57: 1691-1705. 10.1002/glia.20885CrossRefPubMed
61.
Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA: The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr. 2002, 132: 1012-1017.PubMed
62.
Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA. 1998, 95: 3003-3007. 10.1073/pnas.95.6.3003PubMedCentralCrossRefPubMed
63.
Levy P, Robin H, Bertrand F, Kornprobst M, Capeau J: Butyrate-treated colonic Caco-2 cells exhibit defective integrin-mediated signaling together with increased apoptosis and differentiation. J Cell Physiol. 2003, 197: 336-347. 10.1002/jcp.10345CrossRefPubMed
64.
Davido DJ, Richter F, Boxberger F, Stahl A, Menzel T, Luhrs H, Loffler S, Dusel G, Rapp UR, Scheppach W: Butyrate and propionate downregulate ERK phosphorylation in HT-29 colon carcinoma cells prior to differentiation. Eur J Cancer Prev. 2001, 10: 313-321. 10.1097/00008469-200108000-00004CrossRefPubMed
65.
Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, Blottiere HM: Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut. 2000, 46: 507-514. 10.1136/gut.46.4.507PubMedCentralCrossRefPubMed
66.
Baserga R: The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 2000, 19: 5574-5581. 10.1038/sj.onc.1203854CrossRefPubMed
67.
White MF: The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998, 182: 3-11. 10.1023/A:1006806722619CrossRefPubMed
68.
Pete G, Fuller CR, Oldham JM, Smith DR, D'Ercole AJ, Kahn CR, Lund PK: Postnatal growth responses to insulin-like growth factor I in insulin receptor substrate-1-deficient mice. Endocrinology. 1999, 140: 5478-5487. 10.1210/en.140.12.5478PubMed
69.
Chang Q, Li Y, White MF, Fletcher JA, Xiao S: Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res. 2002, 62: 6035-6038.PubMed
70.
Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, Soddu S, Cristofanelli B, Sacchi A, Baserga R: Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem. 1999, 274: 12423-12430. 10.1074/jbc.274.18.12423CrossRefPubMed
71.
Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P: SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004, 166: 37-47. 10.1083/jcb.200311021PubMedCentralCrossRefPubMed
72.
Lu B, Fang Y, Xu J, Wang L, Xu F, Xu E, Huang Q, Lai M: Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008, 130: 897-904. 10.1309/AJCPW1W8GJBQGCNICrossRefPubMed
73.
Bastide P, Darido C, Pannequin J, Kist R, Robine S, Marty-Double C, Bibeau F, Scherer G, Joubert D, Hollande F: Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol. 2007, 178: 635-648. 10.1083/jcb.200704152PubMedCentralCrossRefPubMed
Metadata
Title
IGFBP-rP1, a potential molecule associated with colon cancer differentiation
Authors
Wenjing Ruan
Shuzhen Zhu
Haibing Wang
Fangying Xu
Hong Deng
Yu Ma
Maode Lai
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-281

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation

Research

The promoter for intestinal cell kinase is head-to-head with F-Box 9 and contains functional sites for TCF7L2 and FOXA factors

Research

Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma

Research

Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression

Research

The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis

Research

Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits